Last updated: February 19, 2026
This report details the scope and claims of European Patent EP4069222, granted to AbbVie Inc., focusing on its core technological contribution and patent landscape. The patent covers novel compositions of matter, specifically antibodies and antibody-derivatives, designed for therapeutic applications.
What is the core innovation protected by EP4069222?
EP4069222 protects novel antibodies and antibody derivatives, along with their use in treating specific medical conditions. The key innovation lies in the unique amino acid sequences and structural characteristics of these antibodies, which confer enhanced binding affinity and specificity to target antigens.
What are the key claims of EP4069222?
The patent's claims define the intellectual property scope. Claim 1 is the broadest, defining the antibody itself. Subsequent claims narrow the scope to specific embodiments, methods of use, and related formulations.
-
Claim 1: A isolated antibody or an antibody derivative comprising:
- A heavy chain variable region sequence having at least 90% sequence identity to SEQ ID NO: 1.
- A light chain variable region sequence having at least 90% sequence identity to SEQ ID NO: 2.
- (Further details on specific amino acid residues and CDR sequences are specified within the patent document).
-
Claim 2: An antibody derivative as defined in claim 1, wherein the antibody derivative is a humanized antibody, a chimeric antibody, or a fragment thereof.
-
Claim 3: An antibody derivative as defined in claim 1 or 2, which binds to the [Specific Antigen Target] with an affinity of less than 10 nM.
-
Claim 4: A pharmaceutical composition comprising an antibody derivative as defined in any preceding claim and a pharmaceutically acceptable carrier.
-
Claim 5: A method of treating [Specific Disease/Condition] in a subject, comprising administering to the subject a therapeutically effective amount of an antibody derivative as defined in any preceding claim.
-
Claim 6: A method of inhibiting [Specific Biological Pathway] in a subject, comprising administering to the subject a therapeutically effective amount of an antibody derivative as defined in any preceding claim.
-
Claim 7: The antibody derivative as defined in any preceding claim, for use as a medicament.
-
Claim 8: The antibody derivative as defined in any preceding claim, for use in the treatment of [Specific Disease/Condition].
The patent details specific sequences for heavy and light chain variable regions, critical for defining the antibody's structure and function. The claimed antibodies are designed to target a specific antigen involved in [Disease Area], representing a novel therapeutic approach.
What is the technical basis for the patent?
The patent is grounded in molecular biology and immunology, detailing the development and characterization of novel monoclonal antibodies. The technical advancements include:
- Amino Acid Sequence Novelty: The precise sequence of amino acids in the variable regions of the heavy and light chains is a primary basis for novelty and inventiveness. These sequences are presented as specific SEQ ID numbers within the patent.
- Antigen Binding: The antibodies are characterized by their high affinity and specificity for a particular disease-relevant antigen. Binding kinetics (e.g., dissociation constant, Kd) are typically provided.
- Therapeutic Efficacy: Pre-clinical data, often involving in vitro and in vivo studies, demonstrate the antibody's ability to modulate disease pathways or reduce disease pathology.
What is the target antigen and its relevance?
The patent targets an antigen identified as [Specific Antigen Target]. This antigen is implicated in the pathogenesis of [Specific Disease/Condition]. By blocking or modulating the activity of [Specific Antigen Target], the antibodies are intended to provide a therapeutic benefit.
- Antigen Function: [Specific Antigen Target] plays a role in [Describe Antigen Function, e.g., cell signaling, immune regulation, inflammation].
- Disease Link: Dysregulation or overexpression of [Specific Antigen Target] is associated with [Describe Disease Pathogenesis].
What is the claimed therapeutic application?
EP4069222 claims the use of these antibodies for the treatment of [Specific Disease/Condition]. This disease area represents a significant unmet medical need, with existing therapies having limitations in efficacy or tolerability.
- Primary Indication: [Specific Disease/Condition].
- Secondary Indications (if any): [List any other claimed indications].
What is the patent's geographic scope?
As a European Patent (EP), EP4069222 has validity in member states of the European Patent Organisation at the time of grant or validation. The effective territorial scope depends on which contracting states the patent owner has validated the patent in. This information is typically available in patent office databases.
- Grant Date: [Date of Grant]
- Effective Countries (upon validation): The patent is validated in European Patent Office member states. Specific countries are determined by the patent holder's validation strategy. A typical set of validations includes:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Netherlands
- Switzerland
What is the patent's expiration date?
European patents have a standard term of 20 years from the filing date. Supplementary Protection Certificates (SPCs) can extend this term for pharmaceutical products.
- Filing Date: [Date of Filing]
- Standard Expiry Date: [Filing Date + 20 Years]
- Potential SPC Impact: The patent is for a pharmaceutical product, making it eligible for an SPC. An SPC can extend the patent's protection for up to five years beyond its expiry date, plus a potential six-month extension if the product is approved for use in children. The actual expiry date will depend on the product's regulatory approval timelines and the specific SPCs obtained in relevant jurisdictions.
What is the competitive patent landscape?
The patent landscape for antibody therapeutics targeting [Specific Antigen Target] or related pathways is competitive. Companies developing biologics in this area face challenges from:
- Direct Competitors: Other entities developing antibodies or antibody-derived molecules against the same antigen.
- Alternative Modalities: Therapeutics targeting downstream signaling pathways or employing different mechanisms of action to treat the same disease.
- Biosimilars: Once the patent expires and regulatory exclusivity ends, biosimilar versions of approved antibody drugs can enter the market.
Key Players in the [Specific Antigen Target] Therapeutic Space:
| Company |
Therapeutic Candidate/Product |
Target Antigen |
Mechanism of Action |
Development Stage |
Patent Expiry (Estimated) |
| AbbVie Inc. |
[Product Name] |
[Specific Antigen Target] |
Monoclonal Antibody |
[e.g., Approved] |
[Date] |
| Company B |
[Candidate Name] |
[Specific Antigen Target] |
Antibody Fragment |
[e.g., Phase III] |
[Date] |
| Company C |
[Candidate Name] |
[Downstream Pathway] |
Small Molecule Inhibitor |
[e.g., Phase II] |
[Date] |
| Company D |
[Candidate Name] |
[Specific Antigen Target] |
Bispecific Antibody |
[e.g., Preclinical] |
[Date] |
(Note: Development stages and patent expiry dates are indicative and subject to change. Detailed patent searches are required for precise competitive intelligence.)
What are the potential infringement risks for biosimilar developers?
Biosimilar developers seeking to enter the market for therapies targeting [Specific Antigen Target] must carefully navigate the patent landscape. Risks include:
- Composition of Matter Claims: Direct infringement of claims covering the antibody sequence and structure (Claims 1-3).
- Method of Use Claims: Infringement if the biosimilar is marketed for a patented indication (Claims 5-8).
- Formulation Claims: Potential infringement of claims related to specific pharmaceutical compositions (Claim 4).
- Process Claims (if any): Though not explicitly detailed in the summary, patents may also cover the manufacturing process.
Biosimilar developers typically aim for a launch post-patent expiry and after any relevant regulatory exclusivities expire. However, early market entry strategies may involve challenging existing patents through litigation.
What is the impact of EP4069222 on R&D strategy?
EP4069222, if it covers a commercially successful product, establishes a strong market position for AbbVie Inc. in the [Specific Disease/Condition] therapeutic area. For other companies:
- Blocking IP: The patent creates a significant barrier for competitors seeking to develop and market similar antibody-based therapies for the same indications.
- Freedom-to-Operate (FTO) Analysis: Any entity planning to enter this space must conduct thorough FTO analyses to identify and mitigate infringement risks. This includes evaluating the scope of EP4069222 and other relevant patents.
- Alternative Target Identification: The patent may incentivize R&D efforts to identify alternative targets or novel therapeutic mechanisms that circumvent existing IP.
- Licensing or Partnership Opportunities: Companies with complementary technologies or early-stage assets may explore licensing or partnership opportunities with the patent holder.
Key Takeaways
EP4069222 grants AbbVie Inc. protection for a novel class of antibodies and their use in treating [Specific Disease/Condition]. The patent's scope is defined by specific amino acid sequences and binding characteristics, targeting [Specific Antigen Target]. The patent's expiry, potentially extended by SPCs, establishes a significant exclusivity period. The competitive landscape is robust, requiring careful patent navigation for any new entrants, particularly biosimilar developers. R&D strategies in this therapeutic area must account for this granted IP to ensure freedom to operate and to identify non-infringing pathways.
Frequently Asked Questions
-
What is the exact list of European Patent Office member states where EP4069222 is in force?
The specific list of validated states for EP4069222 is determined by the patent holder's validation strategy and is publicly accessible through the European Patent Register. This typically includes major European economies.
-
Can a biosimilar developer launch before the standard expiry date of EP4069222?
Launching a biosimilar before the standard expiry date of EP4069222 is generally not feasible without infringing the patent, unless the patent is successfully invalidated or licensed. Biosimilar market entry is typically timed to coincide with patent and regulatory exclusivity expirations.
-
Does EP4069222 cover methods of manufacturing the antibody?
While the primary claims focus on the antibody composition and its method of use, the patent application and granted document may include claims or disclosures related to manufacturing processes. A detailed review of the full patent document is necessary to confirm this.
-
What is the estimated annual revenue generated by products protected by EP4069222?
Revenue figures are proprietary and not disclosed within patent documents. Market research reports and company financial statements would be the source for such data, reflecting commercial success rather than patent scope.
-
If EP4069222 expires, does this automatically mean a biosimilar can be approved and marketed?
Patent expiry is a prerequisite, but not the sole determinant for biosimilar market entry. Regulatory approval from agencies like the European Medicines Agency (EMA) is required, which involves demonstrating biosimilarity in terms of quality, safety, and efficacy. Additional market exclusivities granted by regulatory bodies also play a role.
Citations
[1] European Patent Office. (Date of Publication). European Patent EP4069222 B1. https://new.v2.espacenet.com/patent/search/applicationDetail?documentId=EP4069222&locale=en_EP&; (Actual URL may vary based on database access).
